Clinical Trials Logo

Gastroesophageal Reflux Disease clinical trials

View clinical trials related to Gastroesophageal Reflux Disease.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05216133 Enrolling by invitation - Clinical trials for Gastroesophageal Reflux Disease

Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BADBURN)

Start date: March 22, 2023
Phase:
Study type: Observational

A majority of Fire Department of New York (FDNY) World Trade Center (WTC) exposed rescue and recovery workers developed gastroesophageal reflux disease (GERD), a risk factor for Barrett's Esophagus (BE) and subsequent esophageal cancer. There is diminished health-related quality of life and productivity associated with aerodigestive diseases such as GERD and BE. This proposal will leverage the longitudinally phenotyped WTC exposed cohort, validate biomarkers of WTC-aerodigestive disease, and develop novel, noninvasive disease phenotyping of premalignant diseases such as BE, and identify potential targeted therapeutics to improve care.

NCT ID: NCT04306380 Enrolling by invitation - Clinical trials for Gastroesophageal Reflux Disease

Transoral Incisionless Fundoplication Database Repository (TIF)

TIF
Start date: May 20, 2020
Phase:
Study type: Observational

Collect data on individuals who have a transoral incisionless fundoplication (TIF) performed by physicians at Indiana University for the treatment of gastroesophageal reflux disease.

NCT ID: NCT03853772 Enrolling by invitation - Clinical trials for Gastroesophageal Reflux Disease

The Johns Hopkins Heartburn Center Registry

Start date: April 27, 2019
Phase:
Study type: Observational [Patient Registry]

A multi-center, multi-year registry of patients with gastroesophageal reflux disease (GERD) undergoing diagnostic evaluation and/or treatment of GERD and associated diseases and complications.

NCT ID: NCT02759393 Enrolling by invitation - Clinical trials for Gastroesophageal Reflux Disease

Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis

Start date: October 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate whether dexlansoprazole can be as effective as double dose PPI to achieve SSR in high BMI cases with reflux esophagitis in Los Angeles grades A & B.